Everolimus 2mg, 3mg, 5mg; tabs for oral susp. Monitor for new or worsening respiratory symptoms; discontinue, reduce dose, and/or manage with corticosteroids if non-infectious pneumonitis occurs ...

The US FDA has approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast ...

Everolimus is under clinical development by Novartis and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

The European Commission has approved Afinitor (everolimus), made by pharma company Novartis, for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer.

News, May 09, 2011 FDA Okays Everolimus for Rare Type of Pancreatic Cancer Everolimus (Afinitor) has been approved to treat patients with advanced pancreatic neuroendocrine tumors. News ...

Synthetic derivatives of rapamycin have now been approved or are being investigated as therapeutics in cancer (Torisel, temsirolimus; Afinitor, everolimus; ridaforolimus) and in other diseases.

Patients with inoperable kidney cancer saw significant results in local control and cancer-specific survival with stereotactic ablative body radiotherapy.

10 ) Targeted Therapies For people with GEP-NETs that affect the pancreas, the targeted drugs everolimus (Afinitor) and sunitinib (Sutent) have been shown to slow tumor growth and improve survival.

However, bucking that trend is Novartis, which had three approvals — Afinitor [everolimus, for the treatment of renal cell carcinoma], Coartem [artemether and lumefantrine, for the treatment of ...

According to the collective judgment of analysts, 'Revenues- Established Brands- Afinitor/Votubia - Total' should come in at $83.83 million. The estimate points to a change of -23.8% from the year ...